Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Classifica tra le azioni #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Prezzo delle azioni
$41.14
Ultima sincronizzazione: 2026-09-21
Capitalizzazione di mercato
$182.76B
Variazione (1 giorno)
-7.78%
Variazione (1 anno)
-32.24%
Paese
DK
Scambia Novo Nordisk A/S (NOVO-B)

Categoria

Utile per Novo Nordisk A/S (NOVO-B)
Utile nel Jun 2026 TTM: $23.62B
Secondo gli ultimi rapporti finanziari di Novo Nordisk A/S, gli utili attuali della società sono $23.62B. Nel 2024, la società ha registrato un utile di $17.75B, un aumento rispetto a agli utili del 2023, che erano di $15.50B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Novo Nordisk A/S dal 2000 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $23.62B 19.78%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
$33.59B 42.24%
US
$25.20B 6.68%
US
$8.70B -63.17%
US
$21.39B -9.44%
CH
$5.95B -74.82%
US